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Abstract: (1) Background: Neospora caninum is a major cause of abortion in cattle and represents a 
veterinary health problem of great economic significance. In order to identify novel 
chemotherapeutic agents for the treatment of neosporosis, the Medicines for Malaria Venture 
(MMV) Malaria Box, a unique collection of anti-malarial compounds, were screened against N. 
caninum tachyzoites, and the most efficient compounds were characterized in more detail. (2) 
Methods: A N. caninum beta-galactosidase reporter strain grown in human foreskin fibroblasts was 
treated with 390 compounds from the MMV Malaria Box. The IC50s of nine compounds were 
determined, all of which had been previously been shown to be active against another apicomplexan 
parasite, Theileria annulata. The effects of three of these compounds on the ultrastructure of N. 
caninum tachyzoites were further investigated by transmission electron microscopy at different 
timepoints after initiation of drug treatment. (3) Results: Five MMV Malaria Box compounds 
exhibited promising IC50s below 0.2 µM. The compound with the lowest IC50, namely 25 nM, was 
MMV665941. This compound and two others, MMV665807 and MMV009085, specifically induced 
distinct alterations in the tachyzoites. More specifically, aberrant structural changes were first 
observed in the parasite mitochondrion, and subsequently progressed to other cytoplasmic 
compartments of the tachyzoites. The pharmacokinetic (PK) data obtained in mice suggest that 
treatment with MMV665941 could be potentially useful for further in vivo studies. (4) Conclusions: 
We have identified five novel compounds with promising activities against N. caninum, the effects 
of three of these compounds were studies by transmission electron microscopy (TEM). Their modes 
of action are unknown and require further investigation. 
Keywords: antiparasitic chemotherapy; mitochondrion; mode of action; screening; target 
 
1. Introduction 
Apicomplexan parasites, in particular Neospora, Toxoplasma, Cryptosporidium, Eimeria, 
Plasmodium, and Theileria, are important pathogens that affect humans and/or animals. Neospora 
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caninum, which is closely related to Toxoplasma gondii, is a major causative agent of abortion in cattle 
and causes neuromuscular disease in dogs and other domestic animals [1]. 
The definitive hosts of N. caninum are canids, in particular dogs with a worldwide prevalence of 
17%, as estimated in a recent meta-review [2]. Besides cattle, sheep, water buffaloes, and many 
wildlife species can act as intermediate hosts [3]. Since the economic losses due to abortion in cattle 
are high, amounting up to 1.3 billion US dollars per year according to data obtained from 10 countries 
[4], several strategies are considered for the prevention and treatment of bovine neosporosis, namely 
(i) the testing and culling of seropositive animals, (ii) discontinued breeding with offspring from 
seropositive cows, (iii) the vaccination of susceptible and infected animals, and (iv) the 
chemotherapeutical treatment of calves from seropositive cows [5]. Strategies (iii) and (iv) are, 
however, economically viable only if suitable targets and effective formulations for vaccination 
and/or drug treatments are identified [6]. 
Ab initio drug development against neosporosis is certainly not possible due to the high costs 
and low market return compared to other diseases. Consequently, the repurposing of compounds 
effective against other pathogens may constitute a suitable approach. Despite the fact that a wide 
range of compound classes exhibit interesting effects against N. caninum tachyzoites in vitro [6], only 
a few have been demonstrated to be effective in suitable animal models. One example is 
buparvaquone (BPQ), a drug effective against bovine theileriosis [7], currently marketed in Africa. 
BPQ is effective against N. caninum in vitro and in vivo [8], and inhibits the vertical transmission of 
N. caninum [9] and of T. gondii [10] in pregnant mouse models.  
In 2011, to stimulate drug discovery beyond malaria, Medicines for Malaria Venture (MMV) 
created the open-source MMV Malaria Box issuing from three previous screenings of libraries from 
the St. Jude hospital [11,12], from GlaxoSmithKline [13], and from Novartis [14,15]. Further selections 
resulted in 200 drug-like and 200 probe-like compounds with IC50s against Plasmodium falciparum 
blood stages below 4 µM and a more than 10 times lower cytotoxicity against HEK-293 cells [16].  
The Malaria box was freely accessible until 2016. Data on activities, structures, chemical 
properties, cytotoxicity are, however, still openly available (www.mmv.org/mmv-open) and in vitro 
absorption .distribution-metabolism-excretion (ADME) and in vivo pharmacokinetic data is available 
on request. Consequently, preclinical and clinical candidates for a wide range of diseases have been 
identified. The box has been tested against a wide range of pathogens, including apicomplexan 
parasites of medical and economic importance, and the outcome of these studies has been published 
by Van Voorhis et al. [17]. Since that particular study has focused mainly on human diseases, the 
effects on parasites with a merely veterinarian importance, such as N. caninum or Theileria sp. have 
not been extensively covered. Thus, we have screened the Malaria box against N. caninum and T. 
annulata in separate studies, and the results of the screening against T. annulata were published 
elsewhere [18]. Here, we present the results of a differential screening of the Malaria Box against N. 
caninum and their host cells used for in vitro maintenance of these parasites. Nine compounds 
effective against N. caninum and T. annulata, but not against host cells were characterized in more 
detail.  
2. Results 
2.1. Differential Screening 
In a first differential screening, the 390 compounds contained in the MMV Malaria Box were 
screened against human foreskin fibroblasts (HFFs) infected with a N. caninum strain expressing 
Escherichia coli β-galactosidase to determine the effectiveness against N. caninum tachyzoites and 
against uninfected HFFs to determine cytotoxicity. Thirty-nine compounds were effective against N. 
caninum. eleven of these compounds were, however, cytotoxic against HFFs. Of the resulting twenty-
eight compounds (19 were probe-like, nine were drug-like) with specific antiparasitic activity, nine 
were also effective against Theileria annulata (Figure 1). The MMV numbers of the 28 “Hits” are given 
in Table A1 in Appendix A. 
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Figure 1. Scheme of the initial screening procedure of 390 Medicines for Malaria Venture (MMV) 
Malaria Box compounds against Neospora caninum tachyzoites and human foreskin fibroblasts (HFFs). 
The screening was performed as described in Section 4.3. The results of the screening carried out in 
parallel against Theileria annulata were published earlier [18]. 
2.2. Inhibition Curves 
In a next step, the IC50 values of the nine compounds effective against both, N. caninum and T. 
annulata, were determined using a concentration range of 0–250 nM. Four compounds (1–4) had IC50 
values below 0.1 µM, and one compound (5) had IC50 values below 0.2 µM (Figure 2A). The IC50 
values of the four compounds 6–9 were above the concentration range used (Figure 2 B) and had to 
be extrapolated.  
 
Figure 2. Dose response curves of 9 Medicines for Malaria Venture (MMV) Malaria Box compounds. 
Compounds 1–5 inhibit N. caninum proliferation with IC50 values (inhibitory concentration of 50% of 
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the solvent control value) below 200 nM (A), compounds 6–9 are less effective (B). The inhibition of 
N. caninum tachyzoite proliferation was determined using a β-galactosidase reporter strain in the 
presence of a concentration series of compounds added prior to the infection of confluent human 
foreskin fibroblasts by tachyzoites. The mean values ± SE are indicated for quadruplicates. 
Compound (1), MMV665941, had the lowest IC50 with 25 nM. Effectiveness and LogP were not 
correlated since lipophilic compounds, e.g., compounds (1–4), and a hydrophilic compound (5) had 
IC50 values below 0.2 µM (Table 1). 
Table 1. Overview of the nine most effective MMV Malaria Box compounds. The IC50s were 
determined from the inhibition curves depicted in Figure 2 as described in Section 4.4. The IC50 values 
were calculated after the logit-log transformation of the mean values and are given in nM with 95% 
confidence intervals. *, values that were extrapolated. Sources: SJ, St. Jude; G, GlaxoSmithKline; N, 
Novartis. 
Compound MMV-N° ChEMBL_NTD_ID Source LogP IC50 (nM) 
(1) 665941 SJ000140980 SJ 4.76 25 ± 5 
(2) 665807 SJ000010289 SJ 6.06 71 ± 30 
(3) 000787 SJ000117451 SJ 4.71 99 ± 10 
(4) 666054 TCMDC-125549 G 6.15 79 ± 10 
(5) 009085 GNF-Pf-3184 N -1.30 150 ± 30 
(6) 000788 SJ000117455 SJ 4.53 280 ± 80* 
(7) 666080 TCMDC-123701 G 4.64 550 ± 120* 
(8) 006522 GNF-Pf-2807 N 6.06 310 ± 110* 
(9) 006172 TCMDC-123912 G 3.50 430 ± 100* 
The structures of the most effective compounds (1–5) are depicted in Figure 3. 
 
Figure 3. Structures of the five MMV Malaria Box compounds inhibiting N. caninum proliferation in 
vitro with IC50 values below 200 nM. 
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Interestingly, the structure of compound (1) is very similar to crystal violet (which lacks the OH 
group). However, structurally and in terms of its properties, this compound is clearly different from 
crystal violet. 
2.3. Effects on the Ultrastructure of N. Caninum Tachyzoites 
In a next step, we investigated the effects of three of these five compounds, namely compound 
(1), compound (2), compound (5), and dimethyl-sulfoxide (DMSO) as a control, on the parasite 
ultrastructure. The selection of test compounds included the two compounds with the lowest IC50 (1 
and 2), and compound (5), which had an unusually low logP (Table 1).  
In control cultures, N. caninum tachyzoites were located intracellularly, localized within a 
parasitophorous vacuole (PV) that is delineated by a parasitophorous vacuole membrane (PVM), 
which is essentially host cell surface membrane-derived and then modified by the parasites. 
Tachyzoites proliferate within the PV, and thus the number of parasites within the vacuoles increased 
rapidly with time (see Figure 4). Within the PV, tachyzoites were embedded in a matrix, composed 
of the parasitophorous vacuole tubular network (PVN). Structural features of tachyzoites were easily 
identified, including the apical conoid, and secretory organelles including dense granules, 
micronemes, and the rhoptries. Also discernible were the nucleus, the Golgi apparatus, and the 
mitochondrion with an electron-dense matrix (Figure 4). 
 
Figure 4. Transmission electron micrographs (TEM) of N. caninum tachyzoite-infected HFF fixed and 
processed at different timepoints (A = 8 h; B = 14 h; C = 26 h; D = 50 h post-infection). con = conoid, 
dg = dense granules, ga = golgi apparatus, hnuc = host cell nucleus, mic = micronemes, mito = 
mitochondrion, nu = nucleus, pvm = parasitophorous vacuole membrane, pvn = parasitophorous 
vacuole network, rop = rhoptries, T = tachyzoites. The bar in A = 0.8; B = 0.6 µm; C and D = 0.8 µm. 
In cultures treated with compound (1), the number of parasites per vacuole did not notably 
increase compared to the controls no matter what time point was studied, reflecting the significant 
inhibition of proliferation (Figure 5). In addition to a profound inhibition of proliferation, compound 
(1) also induced structural alterations within the tachyzoites, such as the cytoplasmic vacuoles that 
were already detectable after 6 h of treatment. These vacuoles appeared to originate from the 
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mitochondrion, which has lost its electron dense matrix and was not visible anymore (Figure 5A, B). 
At this timepoint, the PVM was not always clearly detectable (Figure 5B). The overall degeneration 
of the tachyzoites progressed with time, vacuolization in the parasite cytoplasm became more 
profound (Figure 5C), and after 48 h of drug treatment, tachyzoites were either completely 
degenerated (Figure 5E) or the cytoplasm was filled with electron-dense material and translucent 
inclusions, which are most likely amylopectin granules (Figure 5D, F). The host cell cytoplasm, the 
nuclei and also the mitochondria appeared to remain unaffected by the treatment with compound 
(1). 
 
Figure 5. TEM of N. caninum tachyzoite-infected HFF treated with a 500 nM compound (1) and fixed 
and processed at different timepoints after the treatment began (A, B = 6 h; C = 12 h; D = 24 h; E, F = 
48 h). apg = amylopectin granules, dg = dense granules, hmito = host cell mitochondrion, hnuc = host 
cell nucleus, mic = micronemes, pv = parasitophorous vacuole, pvm = parasitophorous vacuole 
membrane, T = tachyzoite, vac = vacuolization. The bar in A = 0.6 µm; B = 0.8 µm; C = 0.4 µm; D = 0.5 
µm; E and F = 0.8 µm. 
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In cultures treated with compound (2), only a few alterations, such as vacuolization, lamellated 
membrane, and stacks in some instances could be observed after 6 h of treatment, but the 
mitochondrial matrix remained intact, indicating a slightly delayed effect compared to compound (1) 
(Figure 6A, B). However, after a treatment duration of 12 h (Figure 6 C), the loss of the tachyzoite 
mitochondrial matrix was evident, and residues of cristae were still visible on some vacuolar 
membranes. At 24 h of treatment, a subset of parasites started to exhibit a electron-dense cytoplasm, 
while others still displayed intact structures despite vacuolization (Figure 6D). After 48 h, parasites 
were often seen residing within an electron dense matrix, and containing large numbers of 
amylopectin granules (Figure 6E). The host cells remained largely unaffected. 
 
Figure 6. TEM of N. caninum tachyzoite-infected HFF treated with a 500-nM compound (2) and fixed 
and processed at different timepoints after the treatment began (A, B = 6 h, C = 12 h, D = 24 h, E = 48 
h). apg = amylopectin granules, con= conoid, dg = dense granules, ga = golgi apparatus, hmito = host 
cell mitochondrion, hnuc = host cell nucleus, mic = micronemes, mito = mitochondrion, nu = nucleus, 
pvm = parasitophorous vacuole membrane, pvn = parasitophorous vacuole network, rop = rhoptries, 
T = tachyzoites, vac = vacuolization. The bar in A and B = 0.6 µm; C = 0.3 µm; D = 0.5 µm; E =0.4 µm. 
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In cultures treated with compound (5), tachyzoites forming daughter zoites emerging upon 
endodyogeny were visible throughout the whole experiment. After 6 h and even after 12 h, we 
detected vacuoles with numerous zoites that were either vacuolized or exhibited a fragmented 
cytoplasm, all of which indicated ongoing proliferation despite clear ultrastructural alterations. At 48 
h of treatment, large vacuoles were observed, exhibiting an electron-dense matrix containing 
numerous parasites with altered ultrastructures. Frequently, completely destroyed tachyzoites, still 
enclosed by a vacuole, were observed at this time point (Figure 7). 
 
Figure 7. TEM of N. caninum tachyzoite-infected HFF treated with a 500-nM compound (5) and fixed 
and processed at different timepoints after the treatment began (A, B = 6 h, C = 12 h, D = 24 h, E, F = 
48 h). dg = dense granules, dT = daughter zoites, ga = golgi apparatus, mito = mitochondrion, nu = 
nucleus, vac = vacuolization. The bar in A = 0.4 µm; B and C = 1 µm; D = 0.6 µm; E = 1.2 µm; F = 0.5 
µm. 
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3. Discussion 
An in vitro screening of 390 MMV Malariabox compounds against Neospora caninum yielded in 
the identification of 28 compounds with specific activity against N. caninum. Nine of these 
compounds were also effective against Theileria annulata [18], another apicomplexan parasite 
affecting cattle, transmitted by ticks. Of these nine compounds, the most effective is compound (1) or 
MMV665941, a triphenyl-methanol closely related to crystal violet. MMV665941 was previously also 
shown to be most effective against T. annulata but also clearly toxic for macrophages with a 
therapeutic index of only 2.5 [18]. The fact that, in the present screening, MMV665941 did not affect 
confluent HFFs could indicate that this compound preferentially affects proliferating cells. Moreover, 
MMV665941 was also shown to be moderately effective against Cryptosporidium parvum with an IC50 
of around 0.8 µM [19]. In a recently published study comparing the rapidity of action of MMV 
Malaria Box compounds against Plasmodium falciparum blood forms with the (potential) mode of 
antimalarial action [20], MMV665941 was designated to act more slowly than artesunate, but faster 
than atovaquone. The mechanism of action of this compound is unknown. Studies on MMV665941-
susceptible yeast strains suggested an interference with sterol-dependent processes since two of 
seven susceptible mutants were defective in sterol biosysnthesis [17].  
The closely related crystal violet is a broad-spectrum antiseptic with multiple cellular targets. It 
binds to bacterial cell wall components, to DNA [21], most likely also to other acidic macromolecules 
[22], and uncouples Trypanosoma mitochondria [23]. These multiple targets may explain why this 
compound has not only the lowest IC50, but also the strongest impact on parasite ultrastructure, as 
shown by transmission electron microscopy (TEM). Since the vacuolization of tachyzoites observed 
already after 6 h could correspond to the degradation of mitochondria, the selectivity of MMV665941 
could be due to a preferential action on parasite vs. host mitochondria. In terms of the 
pharmacokinetic properties in mice, MMV665941 appears as the most promising compound of the 
three, due to a maximal plasma concentration (Cmax) of 1.09 µM and a high value for the area under 
the curve from time point 0 to the time point of the last measurable concentration (AUC0-last) (see 
Table A2).  
Interestingly, also in cultures treated with compounds (2) and (5), intact parasite mitochondria 
are seen only at 6 h after treatment, not later. This may indicate that compounds with different 
structures and chemical properties (note the different logP values!) may affect the integrity of 
apicomplexan mitochondria. For instance, endochin-like quinolones affect the ultrastructure of 
mitochondria—as evidenced by digestive vacuoles containing mitochondrial fragments—but not of 
other organelles in N. caninum tachyzoites [24]. In addition, organometallic ruthenium complexes 
were shown to primarily act on mitochondria in Toxoplasma gondii [25], N. caninum [26], and in the 
extracellular protozoan parasite Trypanosoma brucei [27]. 
Compound (2) or MMV665807 is a trifluorinated salicylanilide that acts against P. falciparum 
blood stages very rapidly [20]. For similar compounds, the predicted target is PfATP4, an Na+-
ATPase of the plasma membrane [28,29]. The target in N. caninum is unknown. According to our TEM 
observations at 6 h after treatment, the action of MMV665807 against the parasite seems, however, 
slower than the action of MMV665941, indicating that extrapolations of the action of antimalarials 
against blood forms of P. falciparum to intracellular stages of other apicomplexan parasites should be 
made with caution. 
Compounds (3) and (4) are both 8-hydroxyquinolines. Compound (3), MMV000787, acts very 
slowly against P. falciparum blood forms [20] and inhibits cysteine proteinases in functional assays 
[17]. Compound (4), MMV666054, is also most effective against T. annulata, but with a relatively low 
cytotoxicity against bovine macrophages yielding a therapeutic index of around 18 [18]. Moreover, 
MMV666054 is effective against C. parvum [19] and against the helminth Brugia malayi [17]. 
MMV666054 acts relatively slowly against Plasmodium falciparum blood forms, most likely by 
interfering with heme catabolism [20]. Another potential target is MAP kinase 2, as revealed by 
functional assays with Leishmania donovani MAPK2 [17]. 
Compound (5), the naphthalenediimide MMV009085, is the only hydrophilic compound with a 
submicromolar activity (IC50 = 150 nM) against N. caninum. It is also effective against C. parvum with 
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an IC50 in same range [19]. This compound potentially inhibits hexose uptake, as evidenced by 
selective uptake inhibition studies involving P. falciparum hexose transporter 1 [30]. MMV009085 is 
hydrophilic and may directly interact with the transporter as a hexose analogue. While there are no 
studies on hexose transporters in N. caninum, it has been shown that the closely related T. gondii 
expresses two plasma membrane-associated hexose transporters (TgGT1 and TgST2), and two 
intracellularly localized transporters (TgST1 and TgST3). Surprisingly, TgGT1 and TgST2 are 
nonessential to the parasite, but deletion of TgGT1 and TgGT1/TgST2 was shown to cause a delay in 
intracellular replication, the effect of which could be abolished by adding glutamine as a complement 
substrate [31]. Thus, hexose transporters are nonessential for T. gondii, and possibly for N. caninum, 
and other mechanisms of action could be responsible for the observed effects upon treatment with 
compound (5) in N. caninum tachyzoites.  
In conclusion, we have identified five MMV Malaria box compounds that inhibit the 
proliferation of N. caninum tachyzoites in vitro with IC50s in the range of 25-150 nM. Three of these 
compounds were further studied with respect to their effects on morphology and ultrastructure, 
confirming that they do not only inhibit proliferation but also cause extensive alterations, most 
notably in the parasite mitochondria but also in other cytoplasmic compartments within these 
parasites. How these compounds exert these effects is not known, and respective studies on modes 
of action in N. caninum will require further investigations. In any case, these compounds are 
interesting candidates for follow-up studies in vivo, especially in animal models that allow for the 
monitoring of the vertical transmission of N. caninum, which still remains a major problem that causes 
substantial economic losses. 
4. Materials and Methods 
4.1. Chemicals 
The MMV Malaria Box contains 390 compounds (instead of 400, as initially planned) in the form 
of 10-mM stock solutions in DMSO and was obtained free of charge from the MMV (Geneva, 
Switzerland). Supporting information, including the plate mapping is available at 
https://www.mmv.org/mmv-open/malaria-box/malaria-box-supporting-information. The box was 
stored at −20 C. Biochemical reagents were purchased from Sigma (St. Louis, MO, USA). The culture 
media were from ThermoFisher Scientific (formerly Gibco; Waltham, MA, USA). 
4.2. Cell Culture 
Human foreskin fibroblasts (HFF), Vero cells and transgenic beta-galactosidase expressing 
Neospora caninum were cultivated as described [32]. 
4.3. Differential Screening and Inhibition Curves 
For an initial screen, 390 compounds (1 µM compound/well) were added to human foreskin 
fibroblasts (HFFs) previously seeded in 96-well-plates. DMSO (0.25%) was included as a solvent 
control. HFF monolayers were either left uninfected or were infected with 103 N. caninum beta-
galactosidase expressing tachyzoites per well. After 3 days, N. caninum proliferation was assayed by 
measuring beta-galactosidase activity, and HFF viability was monitored using the Alamar Blue assay. 
This screen was repeated once for confirmation, yielding identical results. Forty compounds showing 
values lower than the cut-off of the beta-galactosidase assay were regarded as effective against N. 
caninum, compounds yielding values lower than the cutoff of the Alamar Blue assay were regarded 
as cytotoxic. Effective compounds without cytotoxicity were regarded as potential hits and were 
retained for further experiments. The IC50 values (inhibitory concentration of 50% of the solvent 
control value) of selected compounds were determined in quadruplicate wells in the same assay set-
up and were calculated as described [33].  
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4.4. Transmission Electron Microscopy 
The transmission electron microscopy of N. caninum-infected HFF monolayers was done as 
previously described [34]. Briefly, HFFs were grown to confluency in 6-well tissue culture devices 
and were infected with freshly isolated N. caninum tachyzoites during 2 h at 37 °C/5% CO2. After one 
wash in PBS, treatments with the compounds (1), (2), and (5) were initiated, all at 500 nM. The controls 
were treated with the corresponding amount of DMSO. After 6, 12, 24, or 48 h, samples were rinsed 
in PBS, and were fixed in 100 mM of cacodylate buffer pH7.3 containing 2.5% glutaraldehyde for 2 h 
at room temperature. The cells were scraped and centrifuged at 1000 g for 10 min at 4 °C and, and 
the resulting pellet was further fixed in the same solution at 4 °C overnight, followed by post-fixation 
in 2% OsO4 in cacodylate buffer for 4 h at 4 °C. Subsequently, the specimens were washed and pre-
stained in Uranyless (Electron Microscopy Sciences, Hatfield, PA, USA), followed by dehydration 
in a graded series of ethanol (30%, 50%, 70%, 90%, and 100%). They were finally embedded in Epon 
820 epoxy resin over a period of 2 days with 3 resin changes. The resin was polymerized at 65 °C for 
24 h, and 80-nm sections were cut on a Reichert and Jung ultramicrotome. The sections were loaded 
onto 300-mesh copper grids (Plano GmbH, Marburg, Germany) and were stained with Uranyless 
and lead citrate as described [24]. 
4.5. Statistics 
To define the cutoff values in the initial screening, compounds were regarded as effective against 
N. caninum when the beta-galactosidase values were lower than the mean values of the controls (8 
replicates) minus three times the standard deviation of these control values. Furthermore, 
compounds were regarded as cytotoxic when the Alamar Blue values were lower than the mean 
values of the untreated controls (8 replicates) minus three times the standard deviation of these 
control values. The IC50 values were calculated after the logit-log transformation of the relative 
growth (RG; control = 1) according to the formula ln (RG/(1 – RG)) = a x ln(drug concentration) + b, 
and the subsequent regression analysis was carried out using the corresponding software tool 
contained in the Excel software package (Microsoft, Seattle, WA, USA). 
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Appendix A 
Table A1. Overview of the 28 Malaria box compounds with specific activity against Neospora caninum. 
The screening was performed as shown in Figure 1 and described in Section 4.3.d, drug-like, p,probe-
like. Those five compounds with IC50s below 200 nM are depicted in bold. 
MMV-N° MMV-N° MMV-N° MMV-N° 
000445p 006172p 019670d 665923p 
000699p 006309p 019918d 665940d 
000787p 006389p 084434p 665941p 
000788d 006522p 085203p 666054p 
000911d 008416p 665807d 666080d 
001246p 009085p 665830p 666687p 
001318d 019555p 665852p 666693d 
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Table A2. Pharmacokinetic data of the compounds (1), (2), and (5) obtained after peroral dosing of 
these compounds in mice. AUC0-last, area under the curve from time point 0 to Tlast; AUC0-inf, AUC0-last 
extrapolated to indefinite time point; Cmax, maximal plasma concentration; MRT0-last, MRT0-inf, mean 
residence time from 0 to Tlast or indefinite; NR, not recorded; p.o., peroral; T1/2, half-life; Tmax, time 
point of maximal concentration; Tlast, time point of last measurable concentration. The data were 
kindly provided MMV. 
Parameter Compound (1) Compound (2) Compound (5) 
MMV-N° 665941 665807 009085 
Administered dose p. o. (µmol/kg) 114 119 114 
Cmax (µM) 1.09 0.062 0.308 
Tmax (h) 5.00 6.33 0.444 
T1/2 (h) NR NR 1.48 
Tlast (h) 9.00 9.00 7.00 
AUC0-last (M*h) 27.2 0.264 0.475 
AUC0-inf (M*h) NR NR 0.486 
MRT0-last (h) 4.80 5.24 1.55 
MRT0-inf (h) NR NR 1.80 
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